1 |
Bachet JB, Rougier P, De Gramont A, Andre T (2010). Rectal cancer and adjuvant chemotherapy: which conclusions? Bull Cancer, 97, 107-22.
|
2 |
Benson III AB, Arnoletti JP, Bekaii-Saab T, et al (2011). Clinical practice guidelines in oncology. J Natl Compr Canc Netw, 9, 1238-89.
DOI
|
3 |
Braun MS, Seymour MT (2011).Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther Adv Med Oncol, 3, 43-52.
DOI
|
4 |
Bray F, Sankila R, Ferlay J, Parkin DM (2002). Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer, 38, 99-166.
DOI
|
5 |
Chibaudel B, Tournigand C, André T, De Gramont A (2012). Therapeutic strategy in unresectable metastatic colorectal cancer. TherAdv Med Oncol, 4, 75-89.
DOI
|
6 |
Corfu-A Study Group (1995). Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J ClinOncol, 13, 921-8.
DOI
|
7 |
De Gramont A, Bosset JF, Milan C, et al (1997). Randomized trial comparing monthly low-dose Folinic Acid and Fluorouracil bolus with bimonthly high-dose Folinic Acid and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J ClinOncol, 15, 808-15.
DOI
|
8 |
Folprecht G, Cunningham D, Ross P, et al (2004). Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol, 15, 1330-8.
DOI
ScienceOn
|
9 |
Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al (1996). Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer, 77, 441-51.
DOI
|
10 |
Hill M, Norman A, Cunningham D, et al (1995). Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J ClinOncol, 13, 2317-23.
DOI
|
11 |
Kemeny N (1987). Role of chemotherapy in the treatment of colorectal carcinoma. Semin Surg Oncol, 3, 190-214.
DOI
|
12 |
Kim JH, Kim HS, Han AR, et al (2012). Irinotecan, leucovorin and 5 fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer. Oncol Letters, 4, 751-4.
DOI
|
13 |
MilanoG, Etienne MC, Cassuto-Viguier E, et al (1992). Influence of sex and age on fluorouracil clearance. J ClinOncol, 10, 1171-5.
DOI
|
14 |
Koca D, Oztop I, Yavuzsen T, Ellidokuz H, Yilmaz U (2011). Evaluation of the efficacy of modified de Gramont and modified Folfox4 regimens for adjuvant therapy of locally advanced rectal cancer. Asian Pac J Cancer Prev, 12, 3181-6.
|
15 |
Kohne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P (2008). Chemotherapy in elderly patients with colorectal cancer. Oncologist, 13, 390-402.
DOI
|
16 |
Meta-analysis Group in Cancer (1998). Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J ClinOncol, 16, 301-8.
DOI
|
17 |
Patel K, Anthoney DA, Crellin AM, et al (2004). Weekly 5-Fluorouracil and Folinic Acid: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Ann Oncol, 15, 568-73.
DOI
|
18 |
Petrelli F, Barni S (2012). Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol, 16, 1093.
|
19 |
Petrelli N, Douglass HO, Herrera L, et al (1989). The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol, 7, 1419-26.
DOI
|
20 |
Sargent DJ, Goldberg RM, Jacobson SD, et al (2001).A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med, 345, 1091-7.
DOI
|
21 |
Scheithauer W, Blum J (2004). Coming to grips with hand-foot syndrome. Oncol, 18, ?-?.
|
22 |
Van KuilenburgABP, Meinsma R, Zoetekouw L,Van Gennip AH (2002). Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutation. Int J Cancer, 101, 253-8.
DOI
|
23 |
Stein BN, Petrelli NJ, Douglass HO, et al (1995). Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer, 75, 11-7.
DOI
|
24 |
Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 92, 205-16.
DOI
ScienceOn
|
25 |
Twelves CJ, Cassidy J (2002). Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? Br J Cancer, 86, 1670-6.
DOI
|
26 |
Zalcberg J, Kerr D, Seymour L, Palmer M (1998).Haematological and non-haematologicaltoxicityafter 5-fluorouraciland leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasingageand cycle number. Tomudex International Study Group. Eur J Cancer, 34, 1871-5.
DOI
|